Nucleai and Adlai Nortye Partner to Identify and Validate Novel Spatial Biomarkers Across Adlai Clinical Trials

CHICAGO–(BUSINESS WIRE)–Nucleai, a leader in AI-powered spatial biology, and Adlai Nortye, a global biopharmaceutical company focused on developing innovative immuno-oncology therapies, today announced a strategic partnership to identify, validate and test novel H&E-based biomarkers across Adlai Nortye’s Phase 2 and 3 clinical trials. The collaboration will initially focus on identifying subjects that could derive benefit from Buparlisib treatment in metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN) patients and will expand to other indications and clinical trials.

Contact us

To request more information or to get a demo, quote for our products, please fill out the form below.

Unsubscribe at any time using the link in our emails.
For details, see our Privacy Policy.

Add Your Heading Text Here